News archive

October 2018

• • October 25, 2018
  • Crown Bioscience

  CrownBio Releases MuBase® 2.0. An Open Access Database of Immuno-Oncology Murine Models

  Updates enhance user experience, provide comprehensive characterization data, and add new models

September 2018

• • September 26, 2018
  • Crown Bioscience

  CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models

  Unique well-characterized prostate models derived from castration resistant and hormone sensitive primary tissue now available for studies

• • September 18, 2018
  • Crown Bioscience

  CrownBio Licenses Translational Breast Cancer Models of Resistance and Metastasis

  CrownBio will market a set of new, highly characterized breast cancer models alongside their industry leading collection of more than 2500 PDX models (HuPrime®).

• • September 10, 2018
  • Crown Bioscience

  CARsgen Therapeutics and CrownBio Complete CAR-T Study for Gastric Cancer

  Claudin18.2 specific CAR-T cells show tumor elimination in PDX models

August 2018

• • August 14, 2018
  • Crown Bioscience

  CrownBio Expands Genetically Engineered Model Selection Via Strategic Alliance with Shanghai Model Organisms Center (...

  Alliance enables researchers to access thousands of GEMMs

July 2018

• • July 27, 2018
  • Crown Bioscience

  CrownBio Expands Novel Humanized Models for Targeted Immunotherapy Development to San Diego, CA Research Center

  Humanized Model Expansion Program begins with PD-1, CTLA-4, and CD137 Models

• • July 19, 2018
  • Crown Bioscience

  CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development i...

  "Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused strategies"

April 2018

• • April 4, 2018
  • Crown Bioscience

  CrownBio Launches New Humanized Target Model for Immunotherapy

  Crown Bioscience enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.

March 2018

• • March 28, 2018
  • Crown Bioscience

  Glycotope Selects CrownBio as a Preclinical Development Partner to Advance Their Immunotherapeutic Pipeline

  Crown Bioscience announces that it has been chosen by Glycotope GmbH as a partner to accelerate their immuno-oncology drug discovery pipeline.

• • March 22, 2018
  • Crown Bioscience

  CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

  Crown Bioscience announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the d...

• • March 13, 2018
  • Crown Bioscience

  CrownBio Enters Strategic Partnership with Phanes Therapeutics to Accelerate Discovery and Development of Phanes’ Nov...

  Crown Bioscience announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.

February 2018

• • February 27, 2018
  • Crown Bioscience

  CAR T-Cell Therapy Platform

  Bioluminescent Imaging Capabilities Accelerate Robust CAR T-Cell Therapy